BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ohashi K, Ishikawa T, Suzuki M, Abe H, Koyama F, Nakano T, Ueki A, Noguchi H, Hasegawa E, Hirosawa S, Kobayashi M, Hirosawa H, Sato K, Fukazawa T, Maruyama Y, Yoshida T. Health-related quality of life on the clinical course of patients with chronic hepatitis C receiving daclatasvir/asunaprevir therapy: A prospective observational study comparing younger (<70) and elderly (≥70) patients. Exp Ther Med 2018;15:970-6. [PMID: 29399105 DOI: 10.3892/etm.2017.5488] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Akiyama MJ, Norton BL, Arnsten JH, Agyemang L, Heo M, Litwin AH. Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy: A Randomized Controlled Trial. Ann Intern Med 2019;170:594-603. [PMID: 30959528 DOI: 10.7326/M18-1715] [Cited by in Crossref: 52] [Cited by in F6Publishing: 29] [Article Influence: 17.3] [Reference Citation Analysis]
2 Atamla M, Khoury J, Dabbah I, Kramsky R, Yaacob A, Veitsman E, Saadi T. Direct antiviral agents for chronic hepatitis C virus infection improve health-related quality of life significantly in the long term. Clin Exp Hepatol 2021;7:258-63. [PMID: 34712826 DOI: 10.5114/ceh.2021.109192] [Reference Citation Analysis]